文献速递认知障碍与痴呆

抗β淀粉样蛋白免疫治疗阿尔茨海默病后的脑体积变化:淀粉样蛋白清除相关假性萎缩

Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy.
PubMed 文献 · Lancet Neurol · 2024-01-01

本文综述抗β淀粉样蛋白免疫治疗试验中观察到的脑体积额外丢失现象,提出将其描述为「淀粉样蛋白清除相关假性萎缩」。现有证据表明该变化仅见于实现β淀粉样蛋白降低的免疫治疗,与斑块清除相容,且未提示与有害效应相关。作者建议尽快开展患者水平分析、纵向随访和尸检研究以明确其长期轨迹和临床相关性。

要点

  • 抗β淀粉样蛋白免疫治疗试验中,接受治疗者出现额外脑体积丢失。
  • 该变化仅见于实现β淀粉样蛋白降低的免疫治疗,与斑块清除相容。
  • 现有证据未提示额外体积变化与有害效应相关。

核心结论

  • 基于当前证据,作者建议将抗β淀粉样蛋白免疫治疗后出现的额外脑体积丢失描述为「淀粉样蛋白清除相关假性萎缩」。
  • 需要更好地理解这些变化的原因和后果,以便对治疗做出知情决策。

研究设计与样本

  • 本文为综述,围绕抗β淀粉样蛋白免疫治疗试验中脑体积变化的观察进行讨论。

主要发现

  • 在抗β淀粉样蛋白免疫治疗试验中,接受治疗的参与者出现了额外的脑体积丢失。
  • 该额外体积变化仅见于实现β淀粉样蛋白降低的免疫治疗,与斑块清除相容。
  • 现有证据未提示该额外体积变化与有害效应相关。

临床怎么用

  • 作者建议尽快对试验数据进行患者水平分析,并结合纵向随访和神经影像数据,以确定这些体积变化的长期轨迹及其临床相关性。
  • 作者认为对接受治疗患者的脑组织进行尸检,并评估其与生前神经影像发现的相关性,是重要优先事项。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been widely used as an outcome measure in clinical trials, with the prediction that disease-modifying treatments would slow loss. However, in trials of anti-amyloid immunotherapy, the participants who received treatment had excess volume loss. Explanations for this observation range from reduction of amyloid β plaque burden and related inflammatory changes through to treatment-induced toxicity. The excess volume changes are characteristic of only those immunotherapies that achieve amyloid β lowering; are compatible with plaque removal; and evidence to date does not suggest an association with harmful effects. Based on the current evidence, we suggest that these changes can be described as amyloid-removal-related pseudo-atrophy. Better understanding of the causes and consequences of these changes is important to enable informed decisions about treatments. Patient-level analyses of data from the trials are urgently needed, along with longitudinal follow-up and neuroimaging data, to determine the long-term trajectory of these volume changes and their clinical correlates. Post-mortem examination of cerebral tissue from treated patients and evaluation of potential correlation with antemortem neuroimaging findings are key priorities.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Belder CRS, Boche D, Nicoll JAR, et al. Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol. 2024. PMID: 39304242. doi:10.1016/S1474-4422(24)00335-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。